A Phase 1b Study of Neratinib, Pertuzumab and Trastuzumab With Taxol (3HT) in Primary Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBC

Trial Profile

A Phase 1b Study of Neratinib, Pertuzumab and Trastuzumab With Taxol (3HT) in Primary Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBC

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Neratinib (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel; Pertuzumab; Trastuzumab
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Sep 2017 Planned End Date changed from 1 Aug 2025 to 1 Dec 2025.
    • 07 Sep 2017 Planned primary completion date changed from 1 Aug 2025 to 1 Dec 2025.
    • 07 Sep 2017 Planned initiation date changed from 1 Aug 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top